The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDX..L Regulatory News (DX.)

  • There is currently no data for DX.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.9 Announcement

26 Jan 2024 07:00

RNS Number : 9768A
DX (Group) PLC
26 January 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

DX (Group) plc

("DX", or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers (the "Code"), DX confirms that as at the date of this announcement, it has in issue 647,199,135 ordinary shares of one penny each.

The International Securities Identification Number for DX's ordinary shares is GB00BJTCG679.

 Enquiries

DX

Paul Ibbetson, Chief Executive Officer David Mulligan, Chief Financial Officer

 

+44 20 3178 6378

(c/o KTZ Communications)

 

 

Moelis & Company UK LLP (Lead Financial Adviser to DX)

Mark Aedy, Yorick van Slingelandt, Chris Raff

 

+44 20 7634 3500

Liberum Capital Limited (Nominated Adviser and Joint Broker to DX)

Nick How

 

+44 20 3100 2000

KTZ Communications (PR Adviser to DX)

Katie Tzouliadis/Robert Morton

 

+44 20 3178 6378

Addleshaw Goddard LLP is acting as legal adviser to DX in connection with the Acquisition.

Important notices relating to financial advisers

Moelis & Company UK LLP ("Moelis"), which is regulated by the FCA in the United Kingdom, is acting exclusively for DX and no one else in connection with the Acquisition and other matters set out in this announcement and will not be responsible to anyone other than DX for providing the protections afforded to clients of Moelis, or for providing advice in connection with the Acquisition or any matter referred to herein. Neither Moelis nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Moelis in connection with this announcement, any statement contained herein or otherwise.

Liberum Capital Limited ("Liberum"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively as nominated adviser and joint corporate broker to DX and for no one else in connection with the Acquisition or any matters referred to in this announcement and will not be responsible to anyone other than DX for providing the protections afforded to its clients nor for providing advice in relation to the Acquisition, the contents of this announcement or any other matters referred to in this announcement. Neither Liberum nor any of its affiliates, respective directors, officers, employees and agents owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person other than DX in connection with the matters referred to in this announcement, or otherwise.

Further information

This announcement is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise.

The Acquisition is subject to English law and to the applicable requirements of the Code, the Panel, AIM Rules, the London Stock Exchange and the FCA.

The Acquisition is made solely by the Scheme Document (or, in the event that the Acquisition is implemented by means of a Takeover Offer, the Offer Document), which, together with the Forms of Proxy, contains the full terms and conditions of the. DX Shareholders are advised to read the formal documentation in relation to the Acquisition carefully. Each DX Shareholder is urged to consult their independent financial adviser regarding the tax consequences of the Acquisition.

This announcement does not constitute a prospectus or a prospectus equivalent document.

If you are in any doubt about the Acquisition, the contents of the Scheme Document or as to the action you should take, you are recommended to seek your own personal financial, tax and/or legal advice immediately from your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser authorised under the Financial Services and Markets Act 2000, if you are in the United Kingdom, or, if not, from another appropriately authorised independent adviser in the relevant jurisdiction.

Overseas jurisdictions

The release, publication or distribution of this announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are not resident in the United Kingdom or who are subject to the laws of any jurisdiction other than the United Kingdom (including Restricted Jurisdictions) should inform themselves about, and observe, any applicable legal or regulatory requirements. Any failure to comply with applicable legal or regulatory requirements of any jurisdiction may constitute a violation of securities laws or regulations in that jurisdiction. To the fullest extent permitted by applicable law or regulations, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person.

This announcement has been prepared for the purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside England.

The Acquisition will not be made, directly or indirectly, in or into or by use of the mails or any other means or instrumentality (including, without limitation, telephonic or electronic) of interstate or foreign commerce of, or any facility of a national, state or other securities exchange of, a Restricted Jurisdiction, and the Acquisition will not be capable of acceptance by any such use, means, instrumentality or facility or from within a Restricted Jurisdiction. Copies of this announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction or any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction.

Further details in relation to DX Shareholders in overseas jurisdictions are contained in the Scheme Document.

Rounding

Certain figures included in this announcement have been subjected to rounding adjustments. Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of figures that precede them.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTVELFLZFLBBBV
Date   Source Headline
30th Jan 20247:00 amRNSCancellation - DX (Group) PLC
29th Jan 20242:16 pmRNSForm 8.3 - DX (Group) plc
29th Jan 202410:54 amRNSForm 8.5 (EPT/RI) - DX (Group) plc
29th Jan 202410:29 amRNSScheme Effective
29th Jan 20249:30 amRNSForm 8.5 (EPT/RI)
26th Jan 202412:06 pmRNSForm 8.3 - DX (Group) plc
26th Jan 202410:22 amRNSForm 8.5 (EPT/RI)
26th Jan 20247:00 amRNSRule 2.9 Announcement
25th Jan 20244:02 pmRNSForm 8.3 -DX GROUP PLC Amendment
25th Jan 20242:12 pmRNSForm 8.3 - DX (Group) plc
25th Jan 20241:03 pmRNSPDMR Dealings
25th Jan 202411:51 amRNSResults of Sanction Hearing
25th Jan 202410:14 amRNSForm 8.5 (EPT/RI) - DX (Group) plc
24th Jan 202411:23 amRNSForm 8.5 (EPT/RI)
23rd Jan 20241:27 pmRNSUpdate on financing arrangements
23rd Jan 202410:43 amRNSForm 8.5 (EPT/RI)
22nd Jan 20242:03 pmRNSForm 8.3 - DX GROUP PLC
22nd Jan 202412:36 pmGNWForm 8.3 - DX (Group) Plc
22nd Jan 202411:09 amRNSForm 8.5 (EPT/RI) - DX (Group) plc
22nd Jan 202411:02 amRNSForm 8.5 (EPT/RI)
19th Jan 20243:29 pmRNSForm 8.3 - DX Group Plc
19th Jan 20242:40 pmPRNForm 8.3 - DX (Group) Plc
19th Jan 202412:11 pmRNSForm 8.3 - DX GROUP PLC
19th Jan 202410:44 amRNSForm 8.5 (EPT/RI) - DX (Group) plc
19th Jan 202410:12 amRNSForm 8.3 - DX (Group) Plc
19th Jan 20249:34 amRNSForm 8.5 (EPT/RI)
18th Jan 202412:52 pmRNSForm 8.3 - DX (Group) plc
18th Jan 20249:22 amRNSForm 8.5 (EPT/RI)
17th Jan 20242:35 pmRNSForm 8.3 - DX (Group) plc
17th Jan 202411:15 amRNSForm 8.5 (EPT/RI)
17th Jan 202410:16 amRNSForm 8.5 (EPT/RI) - DX (Group) plc
16th Jan 20241:17 pmRNSForm 8.3 - DX (Group) plc
16th Jan 202411:47 amRNSForm 8.5 (EPT/RI)
15th Jan 202410:53 amRNSForm 8.5 (EPT/RI)
15th Jan 202410:00 amRNSForm 8.5 (EPT/RI) - DX (Group) Plc
12th Jan 20241:26 pmRNSForm 8.3 - DX (Group) plc
12th Jan 202411:28 amRNSForm 8.5 (EPT/RI)
12th Jan 202410:44 amRNSForm 8.5 (EPT/RI) - DX (Group) Plc
11th Jan 202412:01 pmRNSHolding(s) in Company
11th Jan 20249:32 amRNSForm 8.5 (EPT/RI)
10th Jan 20241:46 pmRNSForm 8.3 - DX (Group) plc
10th Jan 202412:46 pmPRNForm 8.3 - DX (Group) Plc
10th Jan 20249:37 amRNSForm 8.5 (EPT/RI)
9th Jan 202412:40 pmRNSResults of Court Meeting and General Meeting
9th Jan 202412:24 pmPRNForm 8.3 - DX (Group) Plc
9th Jan 20249:29 amRNSForm 8.5 (EPT/RI)
8th Jan 20242:08 pmRNSForm 8.3 - DX (Group) plc
8th Jan 20241:37 pmRNSForm 8.3 - DX (Group) plc
8th Jan 20241:18 pmRNSForm 8.3 - DX (Group) Plc
8th Jan 20249:39 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.